From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine (Q24737418)

Europe PubMed Central

title

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine (English)

0 references

0 references

0 references

1 reference

Bruno Guy

1

0 references

Beatrice Barrere

2

0 references

Claire Malinowski

3

0 references

Melanie Saville

4

0 references

Remy Teyssou

5

0 references

Jean Lang

on focus list of Wikimedia project

6

0 references

language of work or name

English

0 references

publication date

23 September 2011

0 references

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

0 references

volume

29

0 references

issue

42

0 references

page(s)

7229-7241

0 references

ScienceSource

0 references

cites work

Dengue: a continuing global threat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Immune response to dengue virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Construction of intertypic chimeric dengue viruses by substitution of structural protein genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Development of Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

High fidelity of yellow fever virus RNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Neuroblastoma Cell-Adapted Yellow Fever 17D Virus: Characterization of a Viral Variant Associated with Persistent Infection and Decreased Virus Spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Human skin Langerhans cells are targets of dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Differential effects of dengue virus on infected and bystander dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

TRAIL Is a Novel Antiviral Protein against Dengue Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Immunopathological mechanisms in dengue and dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Live flavivirus vaccines: reasons for caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Arguments for live flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Recombination and flavivirus vaccines: a commentary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

A trans-Complementing Recombination Trap Demonstrates a Low Propensity of Flaviviruses for Intermolecular Recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Antibody-enhanced dengue virus infection in primate leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Dengue incidence in urban and rural Cambodia: results from population-based active fever surveillance, 2006-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

The introduction of new vaccines into developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Dengue v2V--new global initiative supporting transition from vaccine to vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094

Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.094